Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Patient involvement in improvements in standard of care

NCRI 2012

Published: 14 Nov 2012

Views: 2915

Rating:

Save

Tom Haswell - VNCRI and NCRN Consumer Liaison Groups

Tom Haswell discusses how he has progressed from being diagnosed with serious lung cancer to becoming involved in various patient groups, working to improve the available of treatment options and helping to improve the standard of care offered to patients in future.

Mr Haswell outlines the increase in patient involvement he has seen and stresses the advantages patients can experience taking part in clinical trials.

Related Videos

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Choosing the right patients for transplant

Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Choosing the right patients for transplant ( Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

A reproducibility study in pulmonary adenocarcinomas supports a revised classification

Dr Erik Thunnissen - VU University Medical Center, Amsterdam, The Netherlands

A reproducibility study in pulmonary adenocarcinomas supports a revised classification ( Dr Erik Thunnissen - VU University Medical Center, Amsterdam, The Netherlands )

ASCO 2023: Lung cancer research highlights

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2023: Lung cancer research highlights ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma

Prof Peter Szlosarek - Barts Cancer Institute, London, UK

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma ( Prof Peter Szlosarek - Barts Cancer Institute, London, UK )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

More from ecancer